EUVIMEDEUVIMED entdecken
Open Access

Androgen Receptor PROTAC ARV-110 Ameliorates Metabolic Complications in a Mouse Model of Polycystic Ovary Syndrome

Jelina Basnet iD, Samar Rezq iD, Alexandra M Huffman iD, Tolulope E Asala iD, Licy L Yanes Cardozo iD, Damian G Romero iD

Endocrinology · 2025

DOI: 10.1210/endocr/bqaf091 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrinology, 2025. Verfasst von Jelina Basnet und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS 39216, USA. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Receptors, Androgen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: American Heart Association, NIGMS NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive-age women. Hyperandrogenemia (HA) is a hallmark of PCOS and is positively associated with metabolic complications. Androgens exert their biological actions through the androgen receptor (AR), which regulates transcriptional activity. Antiandrogens are not recommended for managing metabolic complications in PCOS due to their hepatotoxicity, despite being a viable therapy to treat HA. We hypothesized that the novel AR Proteolysis Targeting Chimera (PROTAC) degrader ARV-110 would downregulate AR protein levels and actions to abolish or mitigate HA-mediated metabolic complications using a well-established HA mouse model of PCOS. Three-week-old female mice were implanted with dihydrotestosterone (DHT) or control pellets. Four weeks later, mice were treated with low- (ARV-110-L, 1 mg/kg.day) or high-dose (ARV-110-H, 10 mg/kg.day) ARV-110 for an additional 8 weeks. ARV-110 dose-dependently reduced AR protein levels in white adipose tissue (WAT), kidney, liver, and ovary. ARV-110 attenuated DHT-induced increases in body weight, fat mass, kidney mass, WAT mass, circulating leptin and antimüllerian hormone, and altered glucose homeostasis. ARV-110-H increased kidney (UACR, KIM-1, NGAL) and liver (ALT, AST, LDH) injury markers and caused severe hepatomegaly, while ARV-110-L mostly spared those deleterious effects. Unbiased proteomics analysis revealed that ARV-110-H treatment severely affected the liver proteome and dysregulated multiple signaling and metabolic canonical pathways, while only minimal effects were observed with ARV-110-L treatment. In summary, our findings underscore the potential of AR PROTACs as a novel therapeutic approach for managing metabolic complications in PCOS, provided the dosing is carefully optimized to avoid adverse effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Ovary SyndromeReceptors, AndrogenAnimalsFemaleMiceDisease Models, AnimalDihydrotestosteroneHyperandrogenismLiverOvaryMice, Inbred C57BL

Stichwörter der Autor:innen

PROTACandrogen receptorandrogenspolycystic ovary syndrome

Substanzen

Receptors, AndrogenDihydrotestosteroneAR protein, mouse

Autor:innen und Institutionen

  • Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS 39216, USA.
  • Mississippi Center of Excellence in Perinatal Research, University of Mississippi Medical Center, Jackson, MS 39216, USA.
  • Women's Health Research Center, University of Mississippi Medical Center, Jackson, MS 39216, USA.
  • Cardiovascular-Renal Research Center, University of Mississippi Medical Center, Jackson, MS 39216, USA.
  • Department of Medicine (Endocrinology), University of Mississippi Medical Center, Jackson, MS 39216, USA.

ORCID-Profile: Jelina Basnet, Samar Rezq, Alexandra M Huffman, Tolulope E Asala, Licy L Yanes Cardozo, Damian G Romero

Förderung

  • American Heart Association
  • NIGMS NIH HHS
  • NHLBI NIH HHS
  • NIDDK NIH HHS
  • NIMHD NIH HHS
  • National Institute of General Medical Sciences
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Basnet, J., Rezq, S., Huffman, A. M., Asala, T. E., Yanes Cardozo, L. L., & Romero, D. G. (2025). Androgen Receptor PROTAC ARV-110 Ameliorates Metabolic Complications in a Mouse Model of Polycystic Ovary Syndrome. Endocrinology. https://doi.org/10.1210/endocr/bqaf091

Vancouver

Basnet J, Rezq S, Huffman AM, Asala TE, Yanes Cardozo LL, Romero DG. Androgen Receptor PROTAC ARV-110 Ameliorates Metabolic Complications in a Mouse Model of Polycystic Ovary Syndrome. Endocrinology. 2025. doi:10.1210/endocr/bqaf091

BibTeX
@article{Basnet2025,
  author = {Basnet, Jelina and Rezq, Samar and Huffman, Alexandra M and Asala, Tolulope E and Yanes Cardozo, Licy L and Romero, Damian G},
  title = {Androgen Receptor PROTAC ARV-110 Ameliorates Metabolic Complications in a Mouse Model of Polycystic Ovary Syndrome},
  journal = {Endocrinology},
  year = {2025},
  doi = {10.1210/endocr/bqaf091}
}
Kostenlos starten →